PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30482227-11	2018	RESULTS: IFN-alpha down-regulated the cyclooxygenase-2 (COX-2) expression in bladder cancer cells through the inhibition of TPL2/NF-kappaB pathway; IFN-alpha also inhibited COX-2 expression by suppressing cAMP signaling through TPL2-ERK mediated PDE4D activity.	Cyclic AMP	205-209	interferon alpha 1	Homo sapiens	9-18	
30482227-11	2018	RESULTS: IFN-alpha down-regulated the cyclooxygenase-2 (COX-2) expression in bladder cancer cells through the inhibition of TPL2/NF-kappaB pathway; IFN-alpha also inhibited COX-2 expression by suppressing cAMP signaling through TPL2-ERK mediated PDE4D activity.	Cyclic AMP	205-209	interferon alpha 1	Homo sapiens	148-157	
30482227-12	2018	Reduction of the intracellular cAMP level by PDE4D potentiated the antitumor effect of IFN-alpha against bladder cancer in vitro and in vivo.	Cyclic AMP	31-35	interferon alpha 1	Homo sapiens	87-96	
30482227-15	2018	The antitumor effects of IFN-alpha and MEK inhibition also depend on the PDE4D-mediated cAMP level in bladder cancer cells.	Cyclic AMP	88-92	interferon alpha 1	Homo sapiens	25-34	
30482227-16	2018	Suppression of the TPL2 phosphorylation and intracellular cAMP level may be possible therapeutic strategies for enhancing the effectiveness of IFN-alpha and MEK inhibitors in bladder cancer treatment.	Cyclic AMP	58-62	interferon alpha 1	Homo sapiens	143-152